FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Thomas Merigan

Research Profile

Disorders

Living Beings

HIV-1
HIV

Chemicals & Drugs

Physiology

Procedures

Anatomy

CD4-Positive T-Lymphocytes

Concepts & Ideas

Leukocyte Count

Co-author Network

Publications

TOP 3
Barbara A Rath; Christof Schütte; Robert W Shafer; Max von Kleist; Kaveh Pouran Yousef; David K Katzenstein; Thomas C Merigan
In Vitro HIV-1 Evolution in Response to Triple Reverse Transcriptase Inhibitors & In Silico Phenotypic Analysis.
Barbara Rath; Richard A Olshen; Jerry Halpern; Thomas C Merigan
Persistence versus reversion of 3TC resistance in HIV-1 determine the rate of emergence of NVP resistance.
Alison A Motsinger; Marylyn Ritchie; Robert W Shafer; Gregory Robbins; Gene D Morse; Line Labbe; Grant R Wilkinson; David B Clifford; Richard T D'Aquila; Victoria A Johnson; Richard B Pollard; Thomas C Merigan; Martin S Hirsch; John P Donahue; Richard B Kim; David W Haas
Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Thomas Merigan (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Barbara A Rath; Christof Schütte; Robert W Shafer; Max von Kleist; Kaveh Pouran Yousef; David K Katzenstein; Thomas C Merigan
In Vitro HIV-1 Evolution in Response to Triple Reverse Transcriptase Inhibitors & In Silico Phenotypic Analysis.
PloS one 2013;8(4):e61102.
2012: Barbara Rath; Richard A Olshen; Jerry Halpern; Thomas C Merigan
Persistence versus reversion of 3TC resistance in HIV-1 determine the rate of emergence of NVP resistance.
Viruses 2012;4(8):1212-34.
2006: Alison A Motsinger; Marylyn Ritchie; Robert W Shafer; Gregory Robbins; Gene D Morse; Line Labbe; Grant R Wilkinson; David B Clifford; Richard T D'Aquila; Victoria A Johnson; Richard B Pollard; Thomas C Merigan; Martin S Hirsch; John P Donahue; Richard B Kim; David W Haas
Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study.
Pharmacogenetics and genomics 2006;16(11):837-45.
2006: Rajesh T Gandhi; John Spritzler; Ellen Chan; David M Asmuth; Benigno Rodriguez; Thomas C Merigan; Martin S Hirsch; Robert W Shafer; Gregory Robbins; Richard B Pollard
Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384.
Journal of acquired immune deficiency syndromes (1999) 2006;42(4):426-34.
2005: Philip D Martin; John F Vickrey; Gheorghe Proteasa; Yurytzy L Jimenez; Zdzislaw Wawrzak; Mark A Winters; Thomas C Merigan; Ladislau Christopher Kovari
"Wide-open" 1.3 A structure of a multidrug-resistant HIV-1 protease as a drug target.
Structure (London, England : 1993) 2005;13(12):1887-95.
2005: David W Haas; Laura M Smeaton; Robert W Shafer; Gregory Robbins; Gene D Morse; Line Labbe; Grant R Wilkinson; David B Clifford; Richard T D'Aquila; Victor De Gruttola; Richard B Pollard; Thomas C Merigan; Martin S Hirsch; Alfred L George; John P Donahue; Richard B Kim
Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study.
The Journal of infectious diseases 2005;192(11):1931-42.
2005: Patrick F Smith; Gregory Robbins; Robert W Shafer; Hulin Wu; Song Yu; Martin S Hirsch; Thomas C Merigan; Jeong-Gun Park; Alan Forrest; Margaret A Fischl; Gene D Morse
Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors.
Antimicrobial agents and chemotherapy 2005;49(8):3558-61.
2005: Thomas B Campbell; Nancy S Shulman; Steven C Johnson; Andrew R Zolopa; Russell K Young; Lane Bushman; Courtney V Fletcher; E Randall Lanier; Thomas C Merigan; Daniel R Kuritzkes
Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005;41(2):236-42.
2005: Mark A Winters; Thomas C Merigan
Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms.
Antimicrobial agents and chemotherapy 2005;49(7):2575-82.
2005: Nancy S Shulman; Jamael Delgado; Ronald J Bosch; Mark A Winters; Elizabeth Johnston; Robert W Shafer; David A Katzenstein; Thomas C Merigan
Nonnucleoside reverse transcriptase inhibitor phenotypic hypersusceptibility can be demonstrated in different assays.
Journal of acquired immune deficiency syndromes (1999) 2005;39(1):78-81.
2005: Mark A Winters; Ron M Kagan; Peter N R Heseltine; Thomas C Merigan
New two-amino acid insertion near codon 70 of the HIV type 1 protease gene.
AIDS research and human retroviruses 2005;21(4):311-3.
2005: Mark A Winters; Ron M Kagan; Ladislau Christopher Kovari; Peter N R Heseltine; Thomas C Merigan
Rare one and two amino acid inserts adjacent to codon 103 of the HIV-1 reverse transcriptase (RT) affect susceptibility to non-nucleoside RT inhibitors.
Antiviral therapy 2005;10(2):363-6.
2004: Elizabeth Johnston; Mark A Winters; Soo-Yon Rhee; Thomas C Merigan; Celia A Schiffer; Robert W Shafer
Association of a novel human immunodeficiency virus type 1 protease substrate cleft mutation, L23I, with protease inhibitor therapy and in vitro drug resistance.
Antimicrobial agents and chemotherapy 2004;48(12):4864-8.
2004: Said H Al-Dhahry; Euan M Scrimgeour; Abdul Raouf Al Suwaid; Mohammed R M Y Al Lawati; Hussein S El Khatim; Muhannad F Al Kobaisi; Thomas C Merigan
Human immunodeficiency virus type 1 infection in Oman: antiretroviral therapy and frequencies of drug resistance mutations.
AIDS research and human retroviruses 2004;20(11):1166-72.
2004: Ron M Kagan; Thomas C Merigan; Mark A Winters; Peter N R Heseltine
Increasing prevalence of HIV-1 reverse transcriptase mutation K65R correlates with tenofovir utilization.
Antiviral therapy 2004;9(5):827-8.
2004: Joseph J Eron; Roy M Gulick; John A Bartlett; Thomas C Merigan; Roberto C Arduino; J. Michael Kilby; Bienvenido Yangco; Adriann Diers; Claude Drobnes; Ralph DeMasi; Michael Greenberg; Tom Melby; Claire Raskino; Pam Rusnak; Ying Zhang; Rebecca Spence; G Diego Miralles
Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV.
The Journal of infectious diseases 2004;189(6):1075-83.
2004: Bradley C Logsdon; John F Vickrey; Philip D Martin; Gheorghe Proteasa; Jay I Koepke; Stanley R Terlecky; Zdzislaw Wawrzak; Mark A Winters; Thomas C Merigan; Ladislau Christopher Kovari
Crystal structures of a multidrug-resistant human immunodeficiency virus type 1 protease reveal an expanded active-site cavity.
Journal of virology 2004;78(6):3123-32.
2004: Ron M Kagan; Mark Winters; Thomas C Merigan; Peter N R Heseltine
HIV type 1 genotypic resistance in a clinical database correlates with antiretroviral utilization.
AIDS research and human retroviruses 2004;20(1):1-9.
2003: Jeffrey M Jacobson; Michael M Lederman; John Spritzler; Hernan Valdez; Pablo Tebas; Gail Skowron; Rui Wang; J Brooks Jackson; Lawrence Fox; Alan Landay; Mark J Gilbert; Dorothy O'Neil; Lynne Bancroft; Lena Al-Harthi; Mark A Jacobson; Thomas C Merigan; Marshall J Glesby
Granulocyte-macrophage colony-stimulating factor induces modest increases in plasma human immunodeficiency virus (HIV) type 1 RNA levels and CD4+ lymphocyte counts in patients with uncontrolled HIV infection.
The Journal of infectious diseases 2003;188(12):1804-14.
2003: Robert W Shafer; Laura M Smeaton; Gregory Robbins; Victor De Gruttola; Snyder Sally; Richard T D'Aquila; Victoria A Johnson; Gene D Morse; Mostafa Nokta; Ana I Martinez; Barbara Gripshover; Pamposh Kaul; Richard Haubrich; Mary Swingle; S Debra McCarty; STEFANO VELLA; Martin S Hirsch; Thomas C Merigan
Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.
The New England journal of medicine 2003;349(24):2304-15.
2003: Gregory Robbins; Victor De Gruttola; Robert W Shafer; Laura M Smeaton; Snyder Sally; Carla Pettinelli; Michael P Dubé; Margaret A Fischl; Richard B Pollard; Robert Delapenha; Linda Gedeon; Charles van der Horst; Robert L Murphy; Mark I Becker; Richard T D'Aquila; STEFANO VELLA; Thomas C Merigan; Martin S Hirsch
Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.
The New England journal of medicine 2003;349(24):2293-303.
2003: Bruce Shiramizu; Dickens Theodore; Roland Bassett; Marc N Coel; Kenneth E Sherman; Marshall J Glesby; Dominic Chow; Beverly Alston; Dodi Colquhoun; Thomas C Merigan; Richard C Reichman; Ruth Berggren; Wendy Jo Burning; Susan W Brobst
Correlation of single photon emission computed tomography parameters as a noninvasive alternative to liver biopsies in assessing liver involvement in the setting of HIV and hepatitis C virus coinfection: a multicenter trial of the Adult AIDS Clinical Trials Group.
Journal of acquired immune deficiency syndromes (1999) 2003;33(3):329-35.
2003: John F Vickrey; Bradley C Logsdon; Gheorghe Proteasa; Sarah Palmer; Mark A Winters; Thomas C Merigan; Ladislau Christopher Kovari
HIV-1 protease variants from 100-fold drug resistant clinical isolates: expression, purification, and crystallization.
Protein expression and purification 2003;28(1):165-72.
2002: Robert L Lobato; Eun-Young Kim; Ron M Kagan; Thomas C Merigan
Genotypic and phenotypic analysis of a novel 15-base insertion occurring between codons 69 and 70 of HIV type 1 reverse transcriptase.
AIDS research and human retroviruses 2002;18(10):733-6.
2002: Shoukat H Qari; Mark Winters; Anne-Mieke Vandamme; Thomas C Merigan; Walid Heneine
A rapid phenotypic assay for detecting multiple nucleoside analogue reverse transcriptase inhibitor-resistant HIV-1 in plasma.
Antiviral therapy 2002;7(2):131-9.
2002: John D Baxter; Thomas C Merigan; Deborah N Wentworth; James D Neaton; Marie L Hoover; Richard Hoetelmans; Stephen C Piscitelli; Werner H A Verbiest; Douglas Mayers
Both baseline HIV-1 drug resistance and antiretroviral drug levels are associated with short-term virologic responses to salvage therapy.
AIDS (London, England) 2002;16(8):1131-8.
2001: Eun-Young Kim; Mark A Winters; Ron M Kagan; Thomas C Merigan
Functional correlates of insertion mutations in the protease gene of human immunodeficiency virus type 1 isolates from patients.
Journal of virology 2001;75(22):11227-33.
2001: Mark A Winters; Thomas C Merigan
Variants other than aspartic acid at codon 69 of the human immunodeficiency virus type 1 reverse transcriptase gene affect susceptibility to nuleoside analogs.
Antimicrobial agents and chemotherapy 2001;45(8):2276-9.
2001: Robert W Shafer; Kurt Hertogs; Andrew R Zolopa; Ann Warford; Stuart Bloor; Bradley J Betts; Thomas C Merigan; R Harrigan; Brendan Larder
High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients.
Journal of clinical microbiology 2001;39(4):1522-9.
2001: Eun-Young Kim; Lotta Vrang; B Oberg; Thomas C Merigan
Anti-HIV type 1 activity of 3'-fluoro-3'-deoxythymidine for several different multidrug-resistant mutants.
AIDS research and human retroviruses 2001;17(5):401-7.
2000: Mark A Winters; K L Coolley; P Cheng; Y A Girard; H Hamdan; Ladislau Christopher Kovari; Thomas C Merigan
Genotypic, phenotypic, and modeling studies of a deletion in the beta3-beta4 region of the human immunodeficiency virus type 1 reverse transcriptase gene that is associated with resistance to nucleoside reverse transcriptase inhibitors.
Journal of virology 2000;74(22):10707-13.
2000: Robert T Schooley; C Spino; Daniel R Kuritzkes; B D Walker; F A Valentine; Martin S Hirsch; E Cooney; G Friedland; S Kundu; Thomas C Merigan; M Juliana McElrath; Avanta Collier; S Plaeger; Ronald T Mitsuyasu; J Kahn; P Haslett; P Uherova; Victor DeGruttola; S Chiu; B Zhang; G Jones; Dawn Bell; N Ketter; T Twadell; D Chernoff; ME Rosandich
Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214.
The Journal of infectious diseases 2000;182(5):1357-64.
2000: Clive Gray; J Lawrence; E A Ranheim; Mark A Vierra; Mary Zupancic; Mark Winters; John D Altman; J Montoya; Andrew R Zolopa; Jonathan M Schapiro; Ashley T Haase; Thomas C Merigan
Highly active antiretroviral therapy results in HIV type 1 suppression in lymph nodes, increased pools of naive T cells, decreased pools of activated T cells, and diminished frequencies of peripheral activated HIV type 1-specific CD8+ T cells.
AIDS research and human retroviruses 2000;16(14):1357-69.
2000: John D Baxter; Douglas Mayers; Deborah N Wentworth; James D Neaton; Marie L Hoover; Mark A Winters; S B Mannheimer; M A Thompson; Donald I Abrams; B J Brizz; John Ioannidis; Thomas C Merigan
A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS.
AIDS (London, England) 2000;14(9):F83-93.
2000: MH Shapero; SK Kundu; Edgar G Engleman; Reiner Laus; WC Van Schooten; Thomas C Merigan
In vivo persistence of donor cells following adoptive transfer of allogeneic dendritic cells in HIV-infected patients.
Cell transplantation 2000;9(3):307-17.
2000: Mark A Winters; John D Baxter; Douglas Mayers; Deborah N Wentworth; Marie L Hoover; James D Neaton; Thomas C Merigan
Frequency of antiretroviral drug resistance mutations in HIV-1 strains from patients failing triple drug regimens. The Terry Beirn Community Programs for Clinical Research on AIDS.
Antiviral therapy 2000;5(1):57-63.
1999: Andrew R Zolopa; Robert W Shafer; Ann Warford; Jose G Montoya; P Hsu; David Katzenstein; Thomas C Merigan; Bradley Efron
HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed.
Annals of internal medicine 1999;131(11):813-21.
1999: David A Katzenstein; S Kundu; John Spritzler; B R Smoller; P Haszlett; F Valentine; Thomas C Merigan
Delayed-type hypersensitivity to recombinant HIV envelope glycoprotein (rgp160) after immunization with homologous antigen.
Journal of acquired immune deficiency syndromes (1999) 1999;22(4):341-7.
1999: S Palmer; Robert W Shafer; Thomas C Merigan
Hydroxyurea enhances the activities of didanosine, 9-[2-(phosphonylmethoxy)ethyl]adenine, and 9-[2-(phosphonylmethoxy)propyl]adenine against drug-susceptible and drug-resistant human immunodeficiency virus isolates.
Antimicrobial agents and chemotherapy 1999;43(8):2046-50.
1999: J Lawrence; Jonathan M Schapiro; Mark Winters; J Montoya; Andrew R Zolopa; Rick Pesano; Bradley Efron; Dean L Winslow; Thomas C Merigan
Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons.
The Journal of infectious diseases 1999;179(6):1356-64.
1999: S Palmer; Robert W Shafer; Thomas C Merigan
Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development.
AIDS (London, England) 1999;13(6):661-7.
1999: JP Kleim; Mark Winters; A Dunkler; J R Suarez; G Riess; I Winkler; Jan Balzarini; D Oette; Thomas C Merigan
Antiviral activity of the human immunodeficiency virus type 1-specific nonnucleoside reverse transcriptase inhibitor HBY 097 alone and in combination with zidovudine in a phase II study. HBY 097/2001 Study Group.
The Journal of infectious diseases 1999;179(3):709-13.
1999: Jonathan M Schapiro; Mark A Winters; J Lawrence; Thomas C Merigan
Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.
AIDS (London, England) 1999;13(3):359-65.
1999: Clive Gray; J Lawrence; Jonathan M Schapiro; John D Altman; Mark A Winters; M Crompton; M Loi; SK Kundu; M M Davis; Thomas C Merigan
Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART).
Journal of immunology (Baltimore, Md. : 1950) 1999;162(3):1780-8.
1999: Jonathan M Schapiro; J Lawrence; R Speck; Mark A Winters; Bradley Efron; R W Coombs; Ann C Collier; Thomas C Merigan
Resistance mutations to zidovudine and saquinavir in patients receiving zidovudine plus saquinavir or zidovudine and zalcitabine plus saquinavir in AIDS clinical trials group 229.
The Journal of infectious diseases 1999;179(1):249-53.
1998: SK Kundu; M Dupuis; A Sette; E Celis; F Dorner; M Eibl; Thomas C Merigan
Role of preimmunization virus sequences in cellular immunity in HIV-infected patients during HIV type 1 MN recombinant gp160 immunization.
AIDS research and human retroviruses 1998;14(18):1669-78.
1998: Thomas C Merigan
Use of PCR to measure HIV viral changes in drug-resistant genes in genital fluids.
Journal of reproductive immunology 1998;41(1-2):177-85.
1998: Mark A Winters; K L Coolley; Y A Girard; D J Levee; H Hamdan; Robert W Shafer; David A Katzenstein; Thomas C Merigan
A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors.
The Journal of clinical investigation 1998;102(10):1769-75.
1998: R W Shafer; Mark A Winters; S Palmer; Thomas C Merigan
Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients.
Annals of internal medicine 1998;128(11):906-11.
1998: Mark A Winters; Jonathan M Schapiro; J Lawrence; Thomas C Merigan
Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment.
Journal of virology 1998;72(6):5303-6.
1998: Clive Gray; Jonathan M Schapiro; Mark A Winters; Thomas C Merigan
Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience.
AIDS research and human retroviruses 1998;14(7):561-9.
1998: SK Kundu; Edgar G Engleman; Claudia Benike; MH Shapero; M Dupuis; WC Van Schooten; M Eibl; Thomas C Merigan
A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients.
AIDS research and human retroviruses 1998;14(7):551-60.
1998: D Zipeto; C Hong; G Gerna; M Zavattoni; David Katzenstein; Thomas C Merigan; Lucy Rasmussen
Geographic and demographic differences in the frequency of human cytomegalovirus gB genotypes 1-4 in immunocompromised patients.
AIDS research and human retroviruses 1998;14(6):533-6.
1998: D Rey; M Hughes; J T Pi; Mark Winters; Thomas C Merigan; David A Katzenstein
HIV-1 reverse transcriptase codon 215 mutation in plasma RNA: immunologic and virologic responses to zidovudine. The AIDS Clinical Trials Group Study 175 Virology Team.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1998;17(3):203-8.
1998: Jonathan M Schapiro; Mark A Winters; Mark A Vierra; S Crawford; Thomas C Merigan
Lymph node human immunodeficiency virus RNA levels and resistance mutations in patients receiving high-dose saquinavir.
The Journal of infectious diseases 1998;177(2):477-80.
1998: Madhusudan Peshwa; Claudia Benike; M Dupuis; SK Kundu; Edgar G Engleman; Thomas C Merigan; WC Van Schooten
Generation of primary peptide-specific CD8+ cytotoxic T-lymphocytes in vitro using allogeneic dendritic cells.
Cell transplantation 1998;7(1):1-9.
1997: Lucy Rasmussen; D Zipeto; R A Wolitz; AH Dowling; Bradley Efron; Thomas C Merigan
Risk for retinitis in patients with AIDS can be assessed by quantitation of threshold levels of cytomegalovirus DNA burden in blood.
The Journal of infectious diseases 1997;176(5):1146-55.
1997: SK Kundu; David Katzenstein; F T Valentine; C Spino; Bradley Efron; Thomas C Merigan
Effect of therapeutic immunization with recombinant gp160 HIV-1 vaccine on HIV-1 proviral DNA and plasma RNA: relationship to cellular immune responses.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1997;15(4):269-74.
1997: Robert W Shafer; Jonathan Eisen; Thomas C Merigan; David A Katzenstein
Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe.
Journal of virology 1997;71(7):5441-8.
1997: SK Kundu; Thomas C Merigan
Heterogeneity of cytokine functions in HIV infection.
Immunology 1997;91(2):234-8.
1997: Mark A Winters; Robert W Shafer; R A Jellinger; G Mamtora; Thomas Gingeras; Thomas C Merigan
Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years.
Antimicrobial agents and chemotherapy 1997;41(4):757-62.
1997: R M Jellinger; Robert W Shafer; Thomas C Merigan
A novel approach to assessing the drug susceptibility and replication of human immunodeficiency virus type 1 isolates.
The Journal of infectious diseases 1997;175(3):561-6.
1997: Robert W Shafer; D J Levee; Mark A Winters; K L Richmond; D Huang; Thomas C Merigan
Comparison of QIAamp HCV kit spin columns, silica beads, and phenol-chloroform for recovering human immunodeficiency virus type 1 RNA from plasma.
Journal of clinical microbiology 1997;35(2):520-2.
1997: M Dupuis; Madhusudan Peshwa; Claudia Benike; SK Kundu; Edgar G Engleman; WC Van Schooten; Thomas C Merigan
Allogeneic dendritic cell induction of HIV-specific cytotoxic T lymphocyte responses from T cells of HIV type 1-infected and uninfected individuals.
AIDS research and human retroviruses 1997;13(1):33-9.
1997: Lucy Rasmussen; C Hong; D Zipeto; S Morris; D Sherman; Sunwen Chou; Richard C Miner; W Lawrence Drew; R Wolitz; AH Dowling; Ann Warford; Thomas C Merigan
Cytomegalovirus gB genotype distribution differs in human immunodeficiency virus-infected patients and immunocompromised allograft recipients.
The Journal of infectious diseases 1997;175(1):179-84.
1996: G F Vanhove; Jonathan M Schapiro; M A Winters; Thomas C Merigan; T F Blaschke
Patient compliance and drug failure in protease inhibitor monotherapy.
JAMA : the journal of the American Medical Association 1996;276(24):1955-6.
1996: Robert W Shafer; M A Winters; A K Iversen; Thomas C Merigan
Genotypic and phenotypic changes during culture of a multinucleoside-resistant human immunodeficiency virus type 1 strain in the presence and absence of additional reverse transcriptase inhibitors.
Antimicrobial agents and chemotherapy 1996;40(12):2887-90.
1996: Mark Holodniy; David Katzenstein; L Mole; M Winters; Thomas C Merigan
Human immunodeficiency virus reverse transcriptase codon 215 mutations diminish virologic response to didanosine-zidovudine therapy in subjects with non-syncytium-inducing phenotype.
The Journal of infectious diseases 1996;174(4):854-7.
1996: Jonathan M Schapiro; M A Winters; F Stewart; Bradley Efron; J Norris; M J Kozal; Thomas C Merigan
The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.
Annals of internal medicine 1996;124(12):1039-50.
1996: Fred Valentine; S Kundu; P A Haslett; David Katzenstein; Laurel Beckett; C Spino; M Borucki; M Vasquez; G Smith; J Korvick; J Kagan; Thomas C Merigan
A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with > or = 400/mm3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137).
The Journal of infectious diseases 1996;173(6):1336-46.
1996: R Ramachandran; David A Katzenstein; M A Winters; S K Kundu; Thomas C Merigan
Polyethylene glycol-modified interleukin-2 and thymosin alpha 1 in human immunodeficiency virus type 1 infection.
The Journal of infectious diseases 1996;173(4):1005-8.
1996: Thomas C Merigan; Robert L Hirsch; A C Fisher; L A Meyerson; G Goldstein; M A Winters
The prognostic significance of serum viral load, codon 215 reverse transcriptase mutation and CD4+ T cells on progression of HIV disease in a double-blind study of thymopentin.
AIDS (London, England) 1996;10(2):159-65.
1996: A K Iversen; Robert W Shafer; K Wehrly; M A Winters; James I Mullins; B Chesebro; Thomas C Merigan
Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy.
Journal of virology 1996;70(2):1086-90.
1995: J A Wagner; H Ross; S Hunt; P Gamberg; Hannah A Valantine; Thomas C Merigan; EB Stinson
Prophylactic ganciclovir treatment reduces fungal as well as cytomegalovirus infections after heart transplantation.
Transplantation 1995;60(12):1473-7.
1995: D Zipeto; S Morris; C Hong; A Dowling; R Wolitz; Thomas C Merigan; Lucy Rasmussen
Human cytomegalovirus (CMV) DNA in plasma reflects quantity of CMV DNA present in leukocytes.
Journal of clinical microbiology 1995;33(10):2607-11.
1995: A K Iversen; E G Shpaer; Allen Rodrigo; M S Hirsch; Bruce D Walker; H W Sheppard; Thomas C Merigan; James I Mullins
Persistence of attenuated rev genes in a human immunodeficiency virus type 1-infected asymptomatic individual.
Journal of virology 1995;69(9):5743-53.
1995: M Dupuis; SK Kundu; Thomas C Merigan
Characterization of HLA-A 0201-restricted cytotoxic T cell epitopes in conserved regions of the HIV type 1 gp160 protein.
Journal of immunology (Baltimore, Md. : 1950) 1995;155(4):2232-9.
1995: Robert W Shafer; A K Iversen; M A Winters; E Aguiniga; David A Katzenstein; Thomas C Merigan
Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team.
The Journal of infectious diseases 1995;172(1):70-8.
1995: M J Kozal; Robert W Shafer; M A Winters; David A Katzenstein; Thomas C Merigan
Clarification of a method to reverse transcribe human immunodeficiency virus RNA.
The Journal of infectious diseases 1995;171(4):1072.
1995: Robert W Shafer; Thomas C Merigan
HIV virology for clinical trials.
AIDS (London, England) 1995;9 Suppl A():S193-202.
1995: Thomas C Merigan
Individualization of therapy using viral markers.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1995;10 Suppl 1():S41-6.
1995: Lucy Rasmussen; S Morris; D Zipeto; J Fessel; R Wolitz; A Dowling; Thomas C Merigan
Quantitation of human cytomegalovirus DNA from peripheral blood cells of human immunodeficiency virus-infected patients could predict cytomegalovirus retinitis.
The Journal of infectious diseases 1995;171(1):177-82.
1995: Robert W Shafer; E Aguiniga; Thomas C Merigan
Quantitative analysis of syncytium-inducing and non-syncytium-inducing virus in patients infected with human immunodeficiency virus type 1.
Journal of clinical microbiology 1995;33(1):212-4.
1994: K L Kroodsma; M J Kozal; K A Hamed; M A Winters; Thomas C Merigan
Detection of drug resistance mutations in the human immunodeficiency virus type 1 (HIV-1) pol gene: differences in semen and blood HIV-1 RNA and proviral DNA.
The Journal of infectious diseases 1994;170(5):1292-5.
1994: M Liu; John L Fahey; Najib Aziz; William G Cumberland; G Skowron; Thomas C Merigan
Zidovudine and dideoxycytidine differ in their effects on human immunodeficiency virus-induced pathologic activation of the immune system. AIDS Clinical Trial Research Group 047.
The Journal of infectious diseases 1994;170(5):1165-71.
1994: R V Ramachandran; David A Katzenstein; R Wood; D H Batts; Thomas C Merigan
Failure of short-term CD4-PE40 infusions to reduce virus load in human immunodeficiency virus-infected persons.
The Journal of infectious diseases 1994;170(4):1009-13.
1994: Lucy Rasmussen; S Morris; R Wolitz; A Dowling; J Fessell; Mark Holodniy; Thomas C Merigan
Deficiency in antibody response to human cytomegalovirus glycoprotein gH in human immunodeficiency virus-infected patients at risk for cytomegalovirus retinitis.
The Journal of infectious diseases 1994;170(3):673-7.
1994: SK Kundu; Thomas C Merigan
Relationship of HIV-1 provirus load, CD8+ CD11+ T cells and HIV-1 envelope-specific cytotoxic T lymphocytes in HIV-infected asymptomatic offients.
Immunology 1994;83(1):81-5.
1994: M J Kozal; K Kroodsma; M A Winters; Robert W Shafer; Bradley Efron; David A Katzenstein; Thomas C Merigan
Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy.
Annals of internal medicine 1994;121(4):263-8.
1994: M J Kozal; Robert W Shafer; M A Winters; David A Katzenstein; E Aguiniga; J Halpern; Thomas C Merigan
HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patients.
Journal of acquired immune deficiency syndromes 1994;7(8):832-8.
1994: Mark Holodniy; L Mole; M Winters; Thomas C Merigan
Diurnal and short-term stability of HIV virus load as measured by gene amplification.
Journal of acquired immune deficiency syndromes 1994;7(4):363-8.
1994: David A Katzenstein; M Winters; J Bubp; D Israelski; E Winger; Thomas C Merigan
Quantitation of human immunodeficiency virus by culture and polymerase chain reaction in response to didanosine after long-term therapy with zidovudine.
The Journal of infectious diseases 1994;169(2):416-9.
1994: Thomas C Merigan; S K Kundu
Human immunodeficiency virus envelope glycoproteins.
Journal of acquired immune deficiency syndromes 1994;7 Suppl 1():S14-20.
1993: M A Winters; Thomas C Merigan
Continuous presence of CD4-PE40 is required for antiviral activity against single-passage HIV isolates and infected peripheral blood mononuclear cells.
AIDS research and human retroviruses 1993;9(11):1091-6.
1993: M A Winters; L B Tan; David A Katzenstein; Thomas C Merigan
Biological variation and quality control of plasma human immunodeficiency virus type 1 RNA quantitation by reverse transcriptase polymerase chain reaction.
Journal of clinical microbiology 1993;31(11):2960-6.
1993: Jose G Montoya; R Wood; David Katzenstein; M Holodny; Thomas C Merigan
Peripheral blood mononuclear cell human immunodeficiency virus type 1 proviral DNA quantification by polymerase chain reaction: relationship to immunodeficiency and drug effect.
Journal of clinical microbiology 1993;31(10):2692-6.
1993: K A Hamed; M A Winters; Mark Holodniy; David A Katzenstein; Thomas C Merigan
Detection of human immunodeficiency virus type 1 in semen: effects of disease stage and nucleoside therapy.
The Journal of infectious diseases 1993;167(4):798-802.
1993: Mark Holodniy; David Katzenstein; M Winters; J Montoya; R Shafer; M Kozal; M Ragni; Thomas C Merigan
Measurement of HIV virus load and genotypic resistance by gene amplification in asymptomatic subjects treated with combination therapy.
Journal of acquired immune deficiency syndromes 1993;6(4):366-9.
1993: R Wood; H Dong; David A Katzenstein; Thomas C Merigan
Quantification and comparison of HIV-1 proviral load in peripheral blood mononuclear cells and isolated CD4+ T cells.
Journal of acquired immune deficiency syndromes 1993;6(3):237-40.
1993: Robert W Shafer; M J Kozal; David A Katzenstein; W H Lipil; I F Johnstone; Thomas C Merigan
Zidovudine susceptibility testing of human immunodeficiency virus type 1 (HIV) clinical isolates.
Journal of virological methods 1993;41(3):297-310.
1993: R Wood; J G Montoya; S K Kundu; David H Schwartz; Thomas C Merigan
Safety and efficacy of polyethylene glycol-modified interleukin-2 and zidovudine in human immunodeficiency virus type 1 infection: a phase I/II study.
The Journal of infectious diseases 1993;167(3):519-25.
1993: G Skowron; Samuel A Bozzette; L Lim; Carla Pettinelli; Herbert H Schaumburg; Joseph C Arezzo; Margaret A Fischl; W G Powderly; D J Gocke; Douglas D Richman; J Pottage; D Antoniskis; G F McKinley; N E Hyslop; G Ray; G Simon; N Reed; M L LoFaro; R B Uttamchandani; L D Gelb; S J Sperber; R L Murphy; John Leedom; M H Grieco; J Zachary; M S Hirsch; S A Spector; J Bigley; W Soo; Thomas C Merigan
Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex.
Annals of internal medicine 1993;118(5):321-30.
1993: M J Kozal; Robert W Shafer; M A Winters; David A Katzenstein; Thomas C Merigan
A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients.
The Journal of infectious diseases 1993;167(3):526-32.
1993: A R Berger; Joseph C Arezzo; Herbert H Schaumburg; G Skowron; Thomas C Merigan; Samuel A Bozzette; David P Richman; W Soo
2',3'-dideoxycytidine (ddC) toxic neuropathy: a study of 52 patients.
Neurology 1993;43(2):358-62.
1993: L Mole; D Israelski; J Bubp; P O'Hanley; Thomas C Merigan; T Blaschke
Pharmacokinetics of zidovudine alone and in combination with oxazepam in the HIV infected patient.
Journal of acquired immune deficiency syndromes 1993;6(1):56-60.
1992: SK Kundu; David Katzenstein; L E Moses; Thomas C Merigan
Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(23):11204-8.
1992: SK Kundu; Thomas C Merigan
Equivalent recognition of HIV proteins, Env, Gag and Pol, by CD4+ and CD8+ cytotoxic T-lymphocytes.
AIDS (London, England) 1992;6(7):643-9.
1992: M A Winters; Mark Holodniy; David A Katzenstein; Thomas C Merigan
Quantitative RNA and DNA gene amplification can rapidly monitor HIV infection and antiviral activity in cell cultures.
PCR methods and applications 1992;1(4):257-62.
1992: Thomas C Merigan; D G Renlund; Susan K Keay; Michael R Bristow; Vaughn A Starnes; J B O'Connell; Silvia Resta-Lenert; D Dunn; P Gamberg; R M Ratkovec
A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation.
The New England journal of medicine 1992;326(18):1182-6.
1992: T R Reid; Thomas C Merigan; T Y Basham
Resistance to interferon-alpha in a mouse B-cell lymphoma involves DNA methylation.
Journal of interferon research 1992;12(2):131-7.
1992: A G Clark; Mark Holodniy; David H Schwartz; David A Katzenstein; Thomas C Merigan
Decrease in HIV provirus in peripheral blood mononuclear cells during zidovudine and human rIL-2 administration.
Journal of acquired immune deficiency syndromes 1992;5(1):52-9.
1992: David A Katzenstein; Mark Holodniy; D M Israelski; S Sengupta; L A Mole; J L Bubp; Thomas C Merigan
Plasma viremia in human immunodeficiency virus infection: relationship to stage of disease and antiviral treatment.
Journal of acquired immune deficiency syndromes 1992;5(2):107-12.
1992: Rodney J Y Ho; Rae Lyn Burke; Thomas C Merigan
Liposome-formulated interleukin-2 as an adjuvant of recombinant HSV glycoprotein gD for the treatment of recurrent genital HSV-2 in guinea-pigs.
Vaccine 1992;10(4):209-13.
1992: Mark Holodniy; M A Winters; Thomas C Merigan
Detection and quantification of gene amplification products by a nonisotopic automated system.
BioTechniques 1992;12(1):36, 38-9.
1992: SK Kundu; Thomas C Merigan
CD8+ CD11+ suppressor cells in HIV-infected asymptomatic patients: effect on HIV-specific cytotoxicity.
Viral immunology 1992;5(1):15-25.
1991: SK Kundu; Thomas C Merigan
Inverse relationship of CD8+CD11+ suppressor T cells with human immunodeficiency virus (HIV)-specific cellular cytotoxicity and natural killer cell activity in HIV infection.
Immunology 1991;74(4):567-71.
1991: Mark Holodniy; David A Katzenstein; D M Israelski; Thomas C Merigan
Reduction in plasma human immunodeficiency virus ribonucleic acid after dideoxynucleoside therapy as determined by the polymerase chain reaction.
The Journal of clinical investigation 1991;88(5):1755-9.
1991: Lucy Rasmussen; CC Matkin; Richard Spaete; C Pachl; Thomas C Merigan
Antibody response to human cytomegalovirus glycoproteins gB and gH after natural infection in humans.
The Journal of infectious diseases 1991;164(5):835-42.
1991: Jonathan Mermin; Mark Holodniy; David A Katzenstein; Thomas C Merigan
Detection of human immunodeficiency virus DNA and RNA in semen by the polymerase chain reaction.
The Journal of infectious diseases 1991;164(4):769-72.
1991: Thomas C Merigan; D A Amato; J Balsley; M Power; W A Price; S Benoit; A Perez-Michael; A Brownstein; A S Kramer; D Brettler
Placebo-controlled trial to evaluate zidovudine in treatment of human immunodeficiency virus infection in asymptomatic patients with hemophilia. NHF-ACTG 036 Study Group.
Blood 1991;78(4):900-6.
1991: Frank van Tiel; L Rasmussen; Thomas C Merigan
Cytomegalovirus-specific cell-mediated immune responses in heart and heart-lung transplant recipients are not predictive for the occurrence of symptomatic CMV disease or tissue rejection.
Journal of interferon research 1991;11(4):221-9.
1991: L Rasmussen; Silvia Resta-Lenert; Thomas C Merigan
Human cytomegalovirus glycoprotein-receptor interactions.
Transplantation proceedings 1991;23(3 Suppl 3):60-3.
1991: Thomas C Merigan
Treatment of cytomegalovirus infection in the AIDS patient.
Transplantation proceedings 1991;23(3 Suppl 3):122-5.
1991: Rodney J Y Ho; K T Chong; Thomas C Merigan
Antiviral activity and dose optimum of recombinant macrophage colony-stimulating factor on herpes simplex genitalis in guinea pigs.
Journal of immunology (Baltimore, Md. : 1950) 1991;146(10):3578-82.
1991: Thomas C Merigan
Treatment of AIDS with combinations of antiretroviral agents.
The American journal of medicine 1991;90(4A):8S-17S.
1991: Mark Holodniy; David A Katzenstein; S Sengupta; A M Wang; C Casipit; David H Schwartz; M Konrad; E Groves; Thomas C Merigan
Detection and quantification of human immunodeficiency virus RNA in patient serum by use of the polymerase chain reaction.
The Journal of infectious diseases 1991;163(4):862-6.
1991: Mark Holodniy; S Kim; David Katzenstein; M Konrad; E Groves; Thomas C Merigan
Inhibition of human immunodeficiency virus gene amplification by heparin.
Journal of clinical microbiology 1991;29(4):676-9.
1991: T Basham; T Holdener; Thomas C Merigan
Intermittent, alternating, and concurrent regimens of zidovudine and 2'-3' dideoxycytidine in the LP-BM5 murine induced immunodeficiency model.
The Journal of infectious diseases 1991;163(4):869-72.
1991: Thomas C Merigan; D A Katzenstein
Relation of the pathogenesis of human immunodeficiency virus infection to various strategies for its control.
Reviews of infectious diseases 1991;13(2):292-302.
1991: David H Schwartz; G Skowron; Thomas C Merigan
Safety and effects of interleukin-2 plus zidovudine in asymptomatic individuals infected with human immunodeficiency virus.
Journal of acquired immune deficiency syndromes 1991;4(1):11-23.
1990: Thomas C Merigan
You can teach an old dog new tricks. How AIDS trials are pioneering new strategies.
The New England journal of medicine 1990;323(19):1341-3.
1990: Thomas C Merigan; Silvia Resta-Lenert
Cytomegalovirus: where have we been and where are we going?
Reviews of infectious diseases 1990;12 Suppl 7():S693-700.
1990: Thomas C Merigan; G Skowron
Safety and tolerance of dideoxycytidine as a single agent. Results of early-phase studies in patients with acquired immunodeficiency syndrome (AIDS) or advanced AIDS-related complex. Study Group of the AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.
The American journal of medicine 1990;88(5B):11S-15S.
1990: T Basham; C D Rios; T Holdener; Thomas C Merigan
Zidovudine (AZT) reduces virus titer, retards immune dysfunction, and prolongs survival in the LP-BM5 murine induced immunodeficiency model.
The Journal of infectious diseases 1990;161(5):1006-9.
1990: Rodney J Y Ho; Rae Lyn Burke; Thomas C Merigan
Physical and biological characterization of antigen presenting liposome formulations: relative efficacy for the treatment of recurrent genital HSV-2 in guinea pigs.
Antiviral research 1990;13(4):187-99.
1990: D Portnoi; A M Stall; David H Schwartz; Thomas C Merigan; Leonore A Herzenberg; T Basham
Zidovudine (azido dideoxythymidine) inhibits characteristic early alterations of lymphoid cell populations in retrovirus-induced murine AIDS.
Journal of immunology (Baltimore, Md. : 1950) 1990;144(5):1705-10.
1989: Susan K Keay; Thomas C Merigan; L Rasmussen
Identification of cell surface receptors for the 86-kilodalton glycoprotein of human cytomegalovirus.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(24):10100-3.
1989: T R Reid; E R Race; B H Wolff; R M Friedman; Thomas C Merigan; T Y Basham
Enhanced in vivo therapeutic response to interferon in mice with an in vitro interferon-resistant B-cell lymphoma.
Cancer research 1989;49(15):4163-9.
1989: M H Skinner; M Hsieh; J Torseth; D Pauloin; G Bhatia; S Harkonen; Thomas C Merigan; Terrence F Blaschke
Pharmacokinetics of rifabutin.
Antimicrobial agents and chemotherapy 1989;33(8):1237-41.
1989: Rodney J Y Ho; Rae Lyn Burke; Thomas C Merigan
Antigen-presenting liposomes are effective in treatment of recurrent herpes simplex virus genitalis in guinea pigs.
Journal of virology 1989;63(7):2951-8.
1989: J Torseth; G Bhatia; S Harkonen; C Child; M Skinner; W S Robinson; Terrence F Blaschke; Thomas C Merigan
Evaluation of the antiviral effect of rifabutin in AIDS-related complex.
The Journal of infectious diseases 1989;159(6):1115-8.
1989: Thomas C Merigan
A personal view of efforts in treatment of human immunodeficiency virus infection in 1988.
The Journal of infectious diseases 1989;159(3):390-9.
1989: S L Brown; R A Miller; Sandra J Horning; D Czerwinski; S M Hart; R McElderry; T Basham; Roger A Warnke; Thomas C Merigan; Ronald Levy
Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon.
Blood 1989;73(3):651-61.
1989: Thomas C Merigan; G Skowron; Samuel A Bozzette; D Richman; R Uttamchandani; Margaret A Fischl; R Schooley; M Hirsch; W Soo; Carla Pettinelli
Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. A phase I and II study.
Annals of internal medicine 1989;110(3):189-94.
1988: Susan K Keay; Nelson N Teng; M Eisenberg; B Story; P W Sellers; Thomas C Merigan
Topical interferon for treating condyloma acuminata in women.
The Journal of infectious diseases 1988;158(5):934-9.
1988: T Y Basham; E R Race; M J Campbell; T R Reid; Ronald Levy; Thomas C Merigan
Synergistic antitumor activity with IFN and monoclonal anti-idiotype for murine B cell lymphoma. Mechanism of action.
Journal of immunology (Baltimore, Md. : 1950) 1988;141(8):2855-60.
1988: T Y Basham; M A Palladino; C C Badger; Irwin D Bernstein; Ronald Levy; Thomas C Merigan
Comparison of combinations of interferons with tumor specific and nonspecific monoclonal antibodies as therapy for murine B- and T-cell lymphomas.
Cancer research 1988;48(15):4196-200.
1988: Susan K Keay; E Petersen; T Icenogle; B J Zeluff; T Samo; D Busch; Cheryl L Newman; W C Buhles; Thomas C Merigan
Ganciclovir treatment of serious cytomegalovirus infection in heart and heart-lung transplant recipients.
Reviews of infectious diseases 1988;10 Suppl 3():S563-72.
1988: J Bissett; M Eisenberg; P Gregory; W S Robinson; Thomas C Merigan
Recombinant fibroblast interferon and immune interferon for treating chronic hepatitis B virus infection: patients' tolerance and the effect on viral markers.
The Journal of infectious diseases 1988;157(5):1076-80.
1988: J W Torseth; P W Berman; Thomas C Merigan
Recombinant HIV structural proteins detect specific cellular immunity in vitro in infected individuals.
AIDS research and human retroviruses 1988;4(1):23-30.
1988: Susan K Keay; L Rasmussen; Thomas C Merigan
Syngeneic monoclonal anti-idiotype antibodies that bear the internal image of a human cytomegalovirus neutralization epitope.
Journal of immunology (Baltimore, Md. : 1950) 1988;140(3):944-8.
1988: A Weinberg; Thomas C Merigan
Recombinant interleukin 2 as an adjuvant for vaccine-induced protection. Immunization of guinea pigs with herpes simplex virus subunit vaccines.
Journal of immunology (Baltimore, Md. : 1950) 1988;140(1):294-9.
1987: Susan K Keay; J Bissett; Thomas C Merigan
Ganciclovir treatment of cytomegalovirus infections in iatrogenically immunocompromised patients.
The Journal of infectious diseases 1987;156(6):1016-21.
1987: Thomas C Merigan
Is recombinant interleukin-2 the best way to deliver interferon-gamma in human disease?
Journal of interferon research 1987;7(5):635-9.
1987: J W Torseth; Gary cohen; Roselyn J Eisenberg; P W Berman; L A Lasky; C P Cerini; C J Heilman; S Kerwar; Thomas C Merigan
Native and recombinant herpes simplex virus type 1 envelope proteins induce human immune T-lymphocyte responses.
Journal of virology 1987;61(5):1532-9.
1984: T Basham; W Smith; Lewis L Lanier; V Morhenn; Thomas C Merigan
Regulation of expression of class II major histocompatibility antigens on human peripheral blood monocytes and Langerhans cells by interferon.
Human immunology 1984;10(2):83-93.
1971: T J Chester; E de Clercq; Thomas C Merigan
Effect of Separate and Combined Injections of Poly rI: Poly rC and Endotoxin on Reticulo-endothelial Activity, Interferon, and Antibody Production in the Mouse.
Infection and immunity 1971;3(4):516-20.
1970: Thomas C Merigan; E De Clercq; G H Bausek
Nonviral interferon inducers.
The Journal of general physiology 1970;56(1):57-75.
1970: E De Clercq; M R Nuwer; Thomas C Merigan
Potentiating Effect of Freund's Adjuvant on Interferon Production by Endotoxin or Poly rI*Poly rC.
Infection and immunity 1970;2(1):69-76.
1969: K T Wong; W S Robinson; Thomas C Merigan
Synthesis of viral-specific ribonucleic Acid in rubella virus-infected cells.
Journal of virology 1969;4(6):901-3.